@CarolineHumer

health & pharma, for Reuters

Joined September 2012
  • Tweets1.2K
  • Following341
  • Followers902
Caroline Humer retweeted
pharmalot@pharmalot18 Dec 2023
Pharmalot.. Pharmalittle.. Good Morning: Illumina will divest Grail after court finds deal was anti-competitive; FDA found problems at Moderna facility & More news.. statnews.com/pharmalot/2023/… #pharma #biotech #FDA #hemophilia #weightloss #obesity #raredisease $NVO $ILMN $GPCR $CKPT

Pharmalittle: Illumina will divest Grail after court finds deal was anti-competitive; FDA found...

Illumina plans to divest Grail, which it bought over the objection of regulators in the U.S. and Europe in August 2021.

statnews.com
1
1
1,942
Caroline Humer retweeted
Reuters
@Reuters15 Dec 2023
Exclusive: US FDA finds control lapses at Moderna manufacturing plant reut.rs/3RIWUBt
7
17
7
39
51,891
Some patients with type 2 diabetes say they are having more difficulty getting reimbursed for drugs like Ozempic as U.S. insurers implement restrictions designed to deter doctors from prescribing the medication for weight loss. reut.rs/3NoCLhF reut.rs/3NoCLhF

Focus: US diabetes patients face delays as insurers tighten Ozempic coverage

Some patients with type 2 diabetes say they are having more difficulty getting reimbursed for drugs like Ozempic as U.S. insurers implement restrictions designed to deter doctors from prescribing the...

reuters.com
1
1
1,075
Researchers return to Alzheimer's vaccines, buoyed by recent drug success reut.rs/40JpR3l reut.rs/40JpR3l
2
1
892
The U.S. government on Monday will start taking orders for another round of free COVID-19 tests for delivery across the country, a Department of Health and Human Services (HHS) spokesperson said. reut.rs/3MQR7Hm reut.rs/3MQR7Hm

US to offer more free COVID tests nationwide

The U.S. government on Monday will start taking orders for another round of free COVID-19 tests for delivery across the country, a Department of Health and Human Services (HHS) spokesperson said.

reuters.com
1
1
844
Caroline Humer retweeted
Reuters
@Reuters10 Oct 2023
Down syndrome families' fight for access to Alzheimer’s trials, treatments reut.rs/48JR1dX
3
7
1
17
56,546
Two U.S. senators are demanding that the nation's three largest insulin makers, Novo Nordisk , Eli Lilly , and Sanofi , provide details by Sept. 15 of their programs to help Americans get their insulin for $35 a month or less. reut.rs/44ygHa9

US senators push drugmakers for details on low-cost insulin programs

Two U.S. senators are demanding that the nation's three largest insulin makers, Novo Nordisk , Eli Lilly , and Sanofi , provide details by Sept. 15 of their programs to help Americans get their...

reuters.com
1
2
1,037
Reimbursement of Novo Nordisk's weight-loss drug Wegovy for the 900,000 people in Denmark who are considered obese would cost the Danish state as much as $4 billion each year, the country's health ministry said on Monday. reut.rs/3KYVeQI
1
2
820
Caroline Humer retweeted
Reuters
@Reuters12 Aug 2023
Once the world's priciest drug at over $2 million, Zolgensma was launched as a possible ‘cure’ for spinal muscular atrophy – a rare disorder which is the leading genetic cause of death in infancy globally. Now, patient outcomes paint a nuanced picture reut.rs/3qBcXXj

Insight: What happens when a $2 million gene therapy is not enough

Baby Ben Kutschke was diagnosed at three months with spinal muscular atrophy, a rare inherited disorder which is the leading genetic cause of death in infancy globally. It leaves children too weak to...

reuters.com
3
5
1
29
53,387
Focus: US psychiatrists prescribe Wegovy to battle medication-induced weight gain reut.rs/45h638B

Focus: US psychiatrists prescribe Wegovy to battle medication-induced weight gain

U.S. psychiatrists are increasingly prescribing the popular weight-loss drug Wegovy to patients who gain weight from medicines used to treat mental disorders, such as schizophrenia or bipolar...

reuters.com
4
2
2
4,157
Insight: Promising new Alzheimer's drugs may benefit whites more than Blacks reut.rs/3OegUsW

Insight: Promising new Alzheimer's drugs may benefit whites more than Blacks

Older Black Americans have twice the rate of dementia as whites but were screened out of clinical trials at a higher rate.

reuters.com
1
2
1
1,832
Alzheimer's disease experts are revamping the way doctors diagnose patients with the progressive brain disorder - the most common type of dementia - by devising a seven-point rating scale based on cognitive and biological changes in the patient. reut.rs/44t10ld

Alzheimer's diagnosis revamp embraces rating scale similar to cancer

Alzheimer's disease experts are revamping the way doctors diagnose patients with the progressive brain disorder - the most common type of dementia - by devising a seven-point rating scale based on...

reuters.com
11
18
6,520
Exclusive: Most patients using weight-loss drugs like Wegovy stop within a year, data show reut.rs/3JQiOP3

EXCLUSIVE: Most patients using weight-loss drugs like Wegovy stop within a year, data show

Only about one-third of patients prescribed a popular weight-loss drug like Novo Nordisk’s Wegovy were still taking it a year later, while total healthcare costs for the group rose sharply, according...

reuters.com
2
6
5
4
10,695
Uninsured US patients pay up to $330 for Eli Lilly’s $25 insulin, Senator Warren says reut.rs/3XMVKXh

Uninsured US patients pay up to $330 for Eli Lilly’s $25 insulin, Senator Warren says

Americans without health insurance pay an average of $98 for Eli Lilly’s generic insulin despite the company’s May 1 pledge to cut its list price to $25 per vial, according to a survey of more than...

reuters.com
2
4
1,615
The imminent move to label aspartame as a possible carcinogen comes after years of advocacy from a leading consumer group in the United States and a handful of cancer scientists hoping to settle a decades-long debate over the sweetener's safety. reut.rs/3rs3YYI

How aspartame made the agenda of the WHO's cancer research arm

The imminent move to label aspartame as a possible carcinogen may settle a decades-long debate over the sweetener's safety.

reuters.com
6
5
2,489
Cigna Group's Express Scripts pharmacy benefits unit will add three biosimilar versions of AbbVie's blockbuster arthritis treatment Humira to its list of preferred drugs, the company said on Monday. reut.rs/3pzhKIx

Cigna to add three Humira biosimilars to drug reimbursement list

Cigna Group's Express Scripts pharmacy benefits unit will add three biosimilar versions of AbbVie's blockbuster arthritis treatment Humira to its list of preferred drugs, the company said on Monday.

reuters.com
3
1
1,572
Novo Nordisk will start selling its hugely popular obesity drug Wegovy in Germany this month, its third European market, but only people who pay from their own pocket or have certain private health insurance plans will be able to get it. reut.rs/46DxVFb

Europe faces long wait for weight-loss drugs as governments eye costs

Novo Nordisk will start selling its hugely popular obesity drug Wegovy in Germany this month, its third European market, but only people who pay from their own pocket or have certain private health...

reuters.com
2
1
1
1,248
The European Medicines Agency is looking into Novo Nordisk's weight-loss drugs Saxenda and Ozempic after "several reports of suicidal risks" were referred to the watchdog, Bloomberg News reported on Monday. reut.rs/3XM2Sms

EU investigates Ozempic, weight-loss drug Saxenda after suicidal thoughts reported

The European Medicines Agency (EMA) is investigating Novo Nordisk's diabetes drug Ozempic and weight-loss treatment Saxenda after Iceland's health regulator flagged three cases of patients thinking...

reuters.com
12
1
10
4,567
Fantastic story by ⁦@NatalieGrover⁩. We could be about to see two very divergent approaches to dealing with Alzheimer’s. It’s a fascinating and also disheartening situation. Because one continent will be wrong. reuters.com/business/healthc…

Focus: European Alzheimer's experts unconvinced by new Eisai, Biogen drug

Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on...

reuters.com
10
23
4
28
27,496
Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on scarce healthcare resources. reut.rs/42GrldQ

Focus: European Alzheimer's experts unconvinced by new Eisai, Biogen drug

Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on...

reuters.com
4
7
7,627
Load more